8-K: Cardlytics Enters $50 Million At-the-Market Equity Distribution Agreement

Cardlytics has established an agreement to potentially sell up to $50 million of its common stock through an at-the-market offering.

Summary

• Cardlytics, Inc. has entered into an Equity Distribution Agreement with Evercore Group L.L.C., BofA Securities, Inc., and Cantor Fitzgerald & Co. to sell shares of its common stock.
• The company may sell up to $50 million worth of shares through this at-the-market (ATM) offering.
• The shares will be sold under a shelf registration statement that was previously declared effective by the SEC on February 9, 2024.
• The company is not obligated to sell any shares under this agreement.
• The sales agents will use commercially reasonable efforts to sell the shares based on the company's instructions, including price and time limits.
• The sales agents may sell the shares directly on the Nasdaq Global Market or in other existing trading markets.
• Cardlytics will pay the sales agents a commission of up to 3.0% of the gross proceeds from each sale, plus legal fees and disbursements.
• The agreement will terminate as set forth in the Equity Distribution Agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The agreement provides financial flexibility, but there is a potential for dilution and market volatility. The offering is a standard financial transaction, not a major positive or negative event.

Positives

• The agreement provides Cardlytics with a flexible way to raise capital.
• The at-the-market offering allows the company to sell shares gradually, potentially minimizing market impact.
• The company has the option not to sell any shares if market conditions are not favorable.

Negatives

• The company will incur commissions of up to 3.0% on the gross proceeds from each sale.
• The sale of shares could potentially dilute existing shareholders' ownership.

Risks

• There is no guarantee that the company will be able to sell all $50 million of shares.
• The market price of the company's stock could be negatively impacted by the sale of new shares.
• The company's stock price could be volatile during the period of the offering.

Future Outlook

The company may issue and sell shares of its common stock from time to time, up to a maximum aggregate offering amount of $50.0 million, but is not obligated to do so.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital, providing flexibility and potentially minimizing market impact compared to traditional underwritten offerings. This type of offering is often used by companies seeking to raise capital opportunistically based on market conditions.

Comparison to Industry Standards

• Many publicly traded companies, particularly in the technology sector, utilize at-the-market (ATM) offerings to raise capital.
• The commission rate of up to 3.0% is within the typical range for ATM offerings.
• The $50 million offering size is relatively modest, suggesting a targeted approach to capital raising rather than a large-scale financing event.
• Comparable companies that have used ATM offerings include those in the software and fintech industries, often to fund growth initiatives or acquisitions.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the company sells a significant number of shares.
• The company will have additional capital to fund its operations and growth initiatives.
• The company's stock price may experience volatility during the offering period.

Next Steps

• Cardlytics may begin selling shares of its common stock through the sales agents.
• The company will monitor market conditions and its capital needs to determine the timing and amount of any share sales.
• The company will file required reports with the SEC regarding the sales of shares.

Key Dates

Keywords

equity distribution agreement, at-the-market offering, common stock, capital raise, sales agents, share dilution, Nasdaq, securities, commission